Viyash Scientific Q2 FY27: Revenue ₹9,879 Mn (+16.2% YoY), PAT ₹847 Mn (+16.1% YoY)
Viyash Scientific Limited reported Q2 FY27 revenue of ₹9,879 Mn, up 16.2% YoY, and PAT of ₹847 Mn, up 16.1% YoY. H1 FY27 revenue reached ₹19,343 Mn (+17.8% YoY) with PAT at ₹1,639 Mn (+49.4% YoY). The company highlighted strong performance and strategic investments in growth areas.
The announcement details strong financial performance with substantial revenue and profit growth, indicating a positive impact on the company's financial health and investor confidence.
The company reported significant year-over-year growth in revenue and profit after tax for both the quarter and the half-year, along with positive commentary from the CEO about strategic investments and growth outlook.
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced its financial results for the quarter and half-year ended September 30, 2026. For the second quarter of fiscal year 2027 (Q2 FY27), the company reported revenue from operations of ₹9,879 million, an increase of 16.2% compared to ₹8,503 million in Q2 FY26. EBITDA for the quarter stood at ₹2,077 million, up 10.3% YoY, with a margin of 21.0%. Profit After Tax (PAT) for Q2 FY27 was ₹847 million, a 16.1% increase from ₹729 million in the same period last year. Adjusted PAT for Q2 FY27 was ₹1,110 million.
For the first half of fiscal year 2027 (H1 FY27), revenue from operations grew by 17.8% to ₹19,343 million from ₹16,419 million in H1 FY26. EBITDA for H1 FY27 increased by 29.9% to ₹4,124 million. PAT for H1 FY27 saw a significant rise of 49.4% to ₹1,639 million, compared to ₹1,098 million in H1 FY26. Adjusted PAT for H1 FY27, assuming a normalized annual ESOP cost of ₹25 crore, was ₹2,040 million.
Dr. Hari Babu Bodepudi, Managing Director and Group CEO, commented, "Viyash Scientific has delivered yet another stellar quarter with H1 revenue up 17.8% and H1 profit after tax (PAT) at INR 164 Cr, up ~50% from last year. H1 adjusted PAT with normalized ESOP cost is INR 204 Cr. The completion of acquisition of BioForLife in Italy strengthens our companion animal platform. We are also investing in new oncology capabilities, in-house companion animal manufacturing facility and expanding our API capacity to meet customer demand. Our focus remains on disciplined execution, R&D-led growth and sustainable value creation for customers and stakeholders."
The company's net debt to EBITDA ratio improved to 0.0x from 0.7x in the previous year. Viyash Scientific Limited will hold an earnings call at 11:00 AM IST on November 14, 2026, to discuss the company's performance and answer participant questions.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.